AsclepiX Therapeutics Inc. has reported the first dose of a novel peptide treatment in Phase 1/2a for Diabetic Macular Edema (DME)
AsciepiX Therapeutics Inc., based in Baltimore, Maryland, has announced that the first patient has been dosed in the Phase 1/2a “CONGO” clinical trial to evaluate… Read More »AsclepiX Therapeutics Inc. has reported the first dose of a novel peptide treatment in Phase 1/2a for Diabetic Macular Edema (DME)